SmallCapNewsRelease: (OTCBB: ACCP) CEO Jeffrey Davis Discusses The Recent FDA Approval of MuGard

FOR IMMEDIATE RELEASE
Jericho, New York, United States of America (Free-Press-Release.com) August 20, 2010 -- JERICHO, NY—(SmallCapNewsRelease)—August 23rd, 2010, Access Pharmaceuticals (OTCBB: ACCP) CEO Jeffrey Davis has recently been interviewed by OutsideIn Research about the company’s FDA approved product MuGard, which is used for treatment and prevention of oral mucositis (OM).

1

SmallCapNewsRelease: (OTCBB: ACCP) CEO Jeffrey Davis Discusses The Recent FDA Approval of MuGard

Welcome visit Our WebSite:

http://www.outsideinresearch.com/qaaccp/

OM is the ulceration of the skin lining in your mouth and esophagus, which is most commonly associated with chemotherapy and radiation treatment in cancer patients. OM has traditionally been treated with simple pain medications because there have been no preventative measures available. MuGards’ recent FDA and EMEA approval will facilitate the commercial launching of MuGard in the U.S., Europe and the Far East.

To view the entire interview with Access Pharmaceuticals CEO Jeffrey Davis, please visit www.outsideinresearch.com/qaaccp/

SmallCapNewsRelease gainers are IntriCon Corp (NASDAQ: IIN) Onvia, Inc (NASDAQ: ONVI) Salesforce.com (NYSE: CRM) Monarch Community Bancorp (NASDAQ: MCBF) Canterbury Park Holding Corp (NASDAQ: CPHC) Vestin Realty Mortgage (NASDAQ: VRTB) Intuit Inc (NASDAQ: INTU) North Valley Bancorp (NASDAQ: NOVB)

SmallCapNewsRelease decliners are Kirkland’s Inc (NASDAQ: KIRK) Tongxin International (NASDAQ: TXICW) Optelecom-NKF Inc (NASDAQ: OPTC) SearchMedia Holdings Limited (AMEX: IDI) Iridium Communications Inc (NASDAQ: IRDMW) Acorn International (NYSE: ATV) Corinthian Colleges (NASDAQ: COCO) NewLead Holdings (NASDAQ: NEWLD)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Small Cap News Release twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send no faxes or emails.

More information can be found online at http://www.outsideinresearch.com/qaaccp/

     access pharmaceuticals ceo     access pharmaceuticals treatment     small cap news release  ACCP     EMEA     FDA Approval     financial news     Jeffrey Davis     research     Salesforce.com     small cap